Literature DB >> 7279115

Effect of L-dopa treatment on cerebral amino acid levels in rats after portocaval anastomosis.

G Zanchin, P Rigotti, N Dussini, F Bettineschi, P Vassanelli, L Battistin.   

Abstract

L-Dopa therapy has been suggested as effective in the reversal of hepatic coma both in humans and in animals. Beneficial effects have been reported also in chronic hepatic encephalopathy. There are many possible mechanisms through which L-dopa could ameliorate this pathological state. The present study was carried out to clarify whether the L-dopa effect could be mediated through an improvement of the brain neutral amino acid patterns, since it competes for the same transport carrier at the blood-brain barrier. A first group of rats was orally administered L-dopa (10 mg/100 g body weight daily) for 1 month following portocaval anastomosis. A second group was intraperitoneally injected (1.5 mg/100 g body weight daily) for 1 week, a month after portocaval shunt. Amino acid levels were determined in plasma and in four cerebral regions. No beneficial effects were observed clinically (in general condition, body weight, or hypertonic posture) in rats receiving L-dopa compared to controls. The large increase of tyrosine, phenylalanine, tryptophan, histidine, and glutamine that occurs in the cerebral tissue after portocaval shunt was also not affected by L-dopa administration. In conclusion, in this experimental condition we had no clinical improvement in shunted animals receiving L-dopa. Moreover, this compound did not seem to influence the pathological increase of aromatic amino acids in the brain, which is considered to play an important role in hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7279115     DOI: 10.1007/BF00963881

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  23 in total

1.  Effects of chronic porto-caval anastomosis on brain tryptophan, tyrosine and 5-hydroxytryptamine.

Authors:  G Curzon; B D Kantamaneni; J C Fernando; M S Woods; J B Cavanagh
Journal:  J Neurochem       Date:  1975-05       Impact factor: 5.372

2.  Portacaval shunt in the rat.

Authors:  S H LEE; B FISHER
Journal:  Surgery       Date:  1961-10       Impact factor: 3.982

3.  Treatment and prevention of acute hepatic encephalopathy by intravenous levodopa.

Authors:  O Abramsky; Z Goldschmidt
Journal:  Surgery       Date:  1974-02       Impact factor: 3.982

4.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

5.  L-dopa in hepatic coma.

Authors:  J E Fischer; F J Funovics; H A Falcao; R I Wesdorp
Journal:  Ann Surg       Date:  1976-04       Impact factor: 12.969

6.  The role of plasma amino acids in hepatic encephalopathy.

Authors:  J E Fischer; J M Funovics; A Aguirre; J H James; J M Keane; R I Wesdorp; N Yoshimura; T Westman
Journal:  Surgery       Date:  1975-09       Impact factor: 3.982

7.  Reversal of ammonia coma in rats by L-dopa: a peripheral effect.

Authors:  L Zieve; W M Doizaki; R F Derr
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

8.  Treatment of chronic hepatic encephalopathy with levodopa.

Authors:  M Lunzer; I M James; J Weinman; S Sherlock
Journal:  Gut       Date:  1974-07       Impact factor: 23.059

9.  Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.

Authors:  H Michel; M Solere; P Granier; G Cauvet; J P Bali; F Pons; H Bellet-Hermann
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

10.  Changes in brain amines following portal flow diversion and acute hepatic coma: effects of levodopa (L-dopa) and intestinal sterilization.

Authors:  J E Fischer; J H James; R Baldessarini
Journal:  Surg Forum       Date:  1972
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.